The ARL8A Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the A-549 human lung adenocarcinoma cell line, engineered to disrupt the ARL8A gene. This product provides a genetically heterogeneous pool of cells with targeted disruption of the ARL8A locus, enabling functional studies of ARL8A in a disease-relevant epithelial context. The polyclonal format preserves population-level diversity while ensuring loss of ARL8A expression, making it suitable for pooled screening, bulk biochemical assays, and physiological investigations without clonal bias.
The A-549 parental line was originally established from a 58-year-old Caucasian male with lung adenocarcinoma and exhibits adherent epithelial morphology. It serves as a widely used model for type II pulmonary epithelial cells, lung cancer biology, and drug metabolism studies. A-549 cells retain key features of adenocarcinoma, including oncogenic signaling pathways and metastatic potential, making them a robust platform for interrogating tumor cell behavior and therapeutic responses.
ARL8A encodes a small GTPase that specifically localizes to lysosomes and regulates their motility and subcellular positioning. As part of the BORC complex regulatory cascade, ARL8A cycles between GTP- and GDP-bound states controlled by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). Active ARL8A recruits the kinesin-1 adaptor SKIP (also known as PLEKHM2) to promote anterograde lysosomal transport along microtubules. This process is critical for lysosomal distribution, autophagic flux, and endosomal trafficking. ARL8A also interacts with the HOPS tethering complex and its subunit VPS41, linking lysosome positioning to membrane fusion events. Through these interactions, ARL8A integrates signals from the mTOR pathway and maintains cellular clearance capacity, with implications for cancer cell migration, invasion, and survival under stress.
In A-549 cells, ARL8A disruption through CRISPR/Cas9-mediated knockout offers a valuable model to dissect lysosomal trafficking in lung adenocarcinoma. Given the importance of lysosome function in nutrient sensing, autophagy, and drug sequestration, loss of ARL8A alters lysosome distribution and may impair cellular responses to chemotherapeutic agents. This model enables investigation into how lysosomal positioning affects signaling pathways that govern tumor progression and therapy resistance. The polyclonal knockout population allows researchers to assess ARL8A-dependent phenotypes without the confounding effects of clonal selection, better reflecting the heterogeneity of tumor cell populations.
Researchers can employ this knockout model in a wide range of applications, including autophagy flux analysis using tandem fluorescent LC3 reporters, immunofluorescence microscopy to visualize lysosomal dispersion, transwell invasion assays to evaluate metastatic potential, and drug sensitivity testing to assess lysosome-mediated chemoresistance. Additionally, these cells are suitable for Western blotting of downstream targets like SKIP and kinesin-1, as well as lysosomal enzyme activity assays. The ARL8A Knockout A-549 Polyclonal Cells provide a versatile tool for studying lysosomal biology in cancer and beyond. For further technical specifications and ordering inquiries, please contact Ascent Research.
